{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:49:46Z","timestamp":1778622586346,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,5,29]],"date-time":"2015-05-29T00:00:00Z","timestamp":1432857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,5,29]],"date-time":"2015-05-29T00:00:00Z","timestamp":1432857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The <jats:italic>PSMD6<\/jats:italic> variant rs831571 has been identified as a susceptibility locus for type 2 diabetes mellitus (T2DM). This study aimed to investigate the association of this variant with therapeutic effects of oral antidiabetic drugs in Chinese T2DM patients. 209 newly diagnosed T2DM patients were randomly assigned to treatment with repaglinide or rosiglitazone for 48 weeks and the therapeutic effects were compared. In the rosiglitazone cohort, rs831571 showed significant associations with fasting plasma glucose (FPG), 2-h glucose and decrement of glycated haemoglobin (HbA1c) levels after 24 weeks of treatment (<jats:italic>P\u2009=\u2009<\/jats:italic>0.0368, 0.0468 and 0.0247, respectively). The C allele was significantly associated with a better attainment of FPG at 24 and 32 weeks (<jats:italic>P<\/jats:italic>\u2009=\u20090.0172 and 0.0257, respectively). Survival analyses showed CC homozygotes were more likely to attain a standard FPG level (<jats:italic>P<\/jats:italic>\u2009=\u20090.0654). In the repaglinide cohort, rs831571 was significantly associated with decreased HbA1c levels after 24 weeks of treatment, the homeostatic model assessment of insulin resistance and fasting insulin level after 48 weeks of treatment with repaglinide (<jats:italic>P<\/jats:italic>\u2009=\u20090.0096, 0235 and 0.0212, respectively). In conclusion, we observed that the <jats:italic>PSMD6<\/jats:italic> variant rs831571 might be associated with the therapeutic effects of rosiglitazone and repaglinide in Chinese T2DM patients. However, these findings need to be confirmed in the future.<\/jats:p>","DOI":"10.1038\/srep10701","type":"journal-article","created":{"date-parts":[[2015,5,29]],"date-time":"2015-05-29T14:27:19Z","timestamp":1432909639000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A variant of PSMD6 is associated with the therapeutic efficacy of oral antidiabetic drugs in Chinese type 2 diabetes patients"],"prefix":"10.1038","volume":"5","author":[{"given":"Miao","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danfeng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqian","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiping","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,29]]},"reference":[{"key":"BFsrep10701_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev.med.56.082103.104724","volume":"57","author":"M Eichelbaum","year":"2006","unstructured":"Eichelbaum, M., Ingelman-Sundberg, M. & Evans, W. E. Pharmacogenomics and individualized drug therapy. Annual review of medicine 57, 119\u2013137 (2006).","journal-title":"Annual review of medicine"},{"key":"BFsrep10701_CR2","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/tpj.2014.18","volume":"14","author":"M Chen","year":"2014","unstructured":"Chen, M. et al. Association of PAX4 genetic variants with oral antidiabetic drugs efficacy in Chinese type 2 diabetes patients. The pharmacogenomics journal 14, 488\u2013492 (2014).","journal-title":"The pharmacogenomics journal"},{"key":"BFsrep10701_CR3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/clpt.2010.351","volume":"89","author":"W Yu","year":"2011","unstructured":"Yu, W. et al. Effects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 diabetes. Clin Pharmacol Ther 89, 437\u2013442 (2011).","journal-title":"Clin Pharmacol Ther"},{"key":"BFsrep10701_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2217\/pgs.14.152","volume":"16","author":"M Chen","year":"2015","unstructured":"Chen, M., Hu, C. & Jia, W. Pharmacogenomics of glinides. Pharmacogenomics 16, 45\u201360 (2015).","journal-title":"Pharmacogenomics"},{"key":"BFsrep10701_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/ng.1019","volume":"44","author":"YS Cho","year":"2012","unstructured":"Cho, Y. S. et al. Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in east Asians. Nature genetics 44, 67\u201372 (2012).","journal-title":"Nature genetics"},{"key":"BFsrep10701_CR6","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1021\/bi061994u","volume":"46","author":"X Wang","year":"2007","unstructured":"Wang, X. et al. Mass spectrometric characterization of the affinity-purified human 26S proteasome complex. Biochemistry 46, 3553\u20133565 (2007).","journal-title":"Biochemistry"},{"key":"BFsrep10701_CR7","doi-asserted-by":"publisher","first-page":"a006734","DOI":"10.1101\/cshperspect.a006734","volume":"2","author":"E Wong","year":"2010","unstructured":"Wong, E. & Cuervo, A. M. Integration of clearance mechanisms: the proteasome and autophagy. Cold Spring Harbor perspectives in biology 2, a006734 (2010).","journal-title":"Cold Spring Harbor perspectives in biology"},{"key":"BFsrep10701_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11010-005-1083-y","volume":"275","author":"M Balasubramanyam","year":"2005","unstructured":"Balasubramanyam, M., Sampathkumar, R. & Mohan, V. Is insulin signaling molecules misguided in diabetes for ubiquitin-proteasome mediated degradation? Molecular and cellular biochemistry 275, 117\u2013125 (2005).","journal-title":"Molecular and cellular biochemistry"},{"key":"BFsrep10701_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mce.2012.12.001","volume":"367","author":"M Bugliani","year":"2013","unstructured":"Bugliani, M. et al. Microarray analysis of isolated human islet transcriptome in type 2 diabetes and the role of the ubiquitin-proteasome system in pancreatic beta cell dysfunction. Molecular and cellular endocrinology 367, 1\u201310 (2013).","journal-title":"Molecular and cellular endocrinology"},{"key":"BFsrep10701_CR10","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJMra041001","volume":"351","author":"HThiazolidinediones Yki-Jarvinen","year":"2004","unstructured":"Yki-Jarvinen, H. Thiazolidinediones. N Engl J Med 351, 1106\u20131118 (2004).","journal-title":"N Engl J Med"},{"key":"BFsrep10701_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejim.2006.09.007","volume":"18","author":"JW Elte","year":"2007","unstructured":"Elte, J. W. & Blickle, J. F. Thiazolidinediones for the treatment of type 2 diabetes. European journal of internal medicine 18, 18\u201325 (2007).","journal-title":"European journal of internal medicine"},{"key":"BFsrep10701_CR12","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/S0140-6736(00)90002-3","volume":"355","author":"K Schoonjans","year":"2000","unstructured":"Schoonjans, K. & Auwerx, J. Thiazolidinediones: an update. Lancet 355, 1008\u20131010 (2000).","journal-title":"Lancet"},{"key":"BFsrep10701_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.cmet.2014.08.005","volume":"20","author":"RE Soccio","year":"2014","unstructured":"Soccio, R. E., Chen, E. R. & Lazar, M. A. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell metabolism 20, 573\u2013591 (2014).","journal-title":"Cell metabolism"},{"key":"BFsrep10701_CR14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1210\/jcem.86.1.7157","volume":"86","author":"HE Lebovitz","year":"2001","unstructured":"Lebovitz, H. E., Dole, J. F., Patwardhan, R., Rappaport, E. B. & Freed, M. I. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86, 280\u2013288 (2001).","journal-title":"J Clin Endocrinol Metab"},{"key":"BFsrep10701_CR15","doi-asserted-by":"publisher","first-page":"e50128","DOI":"10.1371\/journal.pone.0050128","volume":"8","author":"HS Kim","year":"2013","unstructured":"Kim, H. S. et al. PPAR-gamma activation increases insulin secretion through the up-regulation of the free fatty acid receptor GPR40 in pancreatic beta-cells. PloS one 8, e50128 (2013).","journal-title":"PloS one"},{"key":"BFsrep10701_CR16","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S0140-6736(01)06715-0","volume":"358","author":"A Dornhorst","year":"2001","unstructured":"Dornhorst, A. Insulinotropic meglitinide analogues. Lancet 358, 1709\u20131716 (2001).","journal-title":"Lancet"},{"key":"BFsrep10701_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2165\/00002512-200017050-00007","volume":"17","author":"R Landgraf","year":"2000","unstructured":"Landgraf, R. Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drugs Aging 17, 411\u2013425 (2000).","journal-title":"Drugs Aging"},{"key":"BFsrep10701_CR18","doi-asserted-by":"publisher","first-page":"936","DOI":"10.5114\/aoms.2013.34991","volume":"9","author":"R Guardado-Mendoza","year":"2013","unstructured":"Guardado-Mendoza, R., Prioletta, A., Jimenez-Ceja, L. M., Sosale, A. & Folli, F. The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus. Archives of medical science : AMS 9, 936\u2013943 (2013).","journal-title":"Archives of medical science : AMS"},{"key":"BFsrep10701_CR19","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.2337\/diacare.27.6.1265","volume":"27","author":"J Rosenstock","year":"2004","unstructured":"Rosenstock, J. et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 27, 1265\u20131270 (2004).","journal-title":"Diabetes Care"},{"key":"BFsrep10701_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2165\/11207600-000000000-00000","volume":"72","author":"LJ Scott","year":"2012","unstructured":"Scott, L. J. Repaglinide: a review of its use in type 2 diabetes mellitus. Drugs 72, 249\u2013272 (2012).","journal-title":"Drugs"},{"key":"BFsrep10701_CR21","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1530\/EJE-14-0052","volume":"170","author":"FS Fang","year":"2014","unstructured":"Fang, F. S. et al. Comparison of repaglinide and metformin monotherapy as an initial therapy in Chinese patients with newly diagnosed type 2 diabetes mellitus. European journal of endocrinology \/ European Federation of Endocrine Societies 170, 901\u2013908 (2014).","journal-title":"European journal of endocrinology \/ European Federation of Endocrine Societies"},{"key":"BFsrep10701_CR22","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1463-1326.2006.00638.x","volume":"9","author":"J Li","year":"2007","unstructured":"Li, J. et al. Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial. Diabetes Obes Metab 9, 558\u2013565 (2007).","journal-title":"Diabetes Obes Metab"},{"key":"BFsrep10701_CR23","first-page":"294017","volume":"2014","author":"J Ma","year":"2014","unstructured":"Ma, J. et al. Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China. Journal of diabetes research 2014, 294017 2014).","journal-title":"Journal of diabetes research"},{"key":"BFsrep10701_CR24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.tcb.2010.03.007","volume":"20","author":"L Paine","year":"2010","unstructured":"Bedford, L., Paine, S., Sheppard, P. W., Mayer, R. J. & Roelofs, J. Assembly, structure and function of the 26S proteasome. Trends in cell biology 20, 391\u2013401 (2010).","journal-title":"Trends in cell biology"},{"key":"BFsrep10701_CR25","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.cell.2010.11.012","volume":"143","author":"MJ Clague","year":"2010","unstructured":"Clague, M. J. & Urbe, S. Ubiquitin: same molecule, different degradation pathways. Cell 143, 682\u2013685 (2010).","journal-title":"Cell"},{"key":"BFsrep10701_CR26","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/jmcb\/mjq030","volume":"2","author":"Y Xie","year":"2010","unstructured":"Xie, Y. Structure, assembly and homeostatic regulation of the 26S proteasome. Journal of molecular cell biology 2, 308\u2013317 (2010).","journal-title":"Journal of molecular cell biology"},{"key":"BFsrep10701_CR27","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1186\/1471-2091-9-S1-S6","volume":"9","author":"SS Wing","year":"2008","unstructured":"Wing, S. S. The UPS in diabetes and obesity. BMC biochemistry 9 (Suppl 1), S6 (2008).","journal-title":"BMC biochemistry"},{"key":"BFsrep10701_CR28","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1186\/1471-2091-9-S1-S7","volume":"9","author":"MD Petroski","year":"2008","unstructured":"Petroski, M. D. The ubiquitin system, disease and drug discovery. BMC biochemistry 9 (Suppl 1), S7 (2008).","journal-title":"BMC biochemistry"},{"key":"BFsrep10701_CR29","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/00075197-200405000-00002","volume":"7","author":"S Rome","year":"2004","unstructured":"Rome, S., Meugnier, E. & Vidal, H. The ubiquitin-proteasome pathway is a new partner for the control of insulin signaling. Current opinion in clinical nutrition and metabolic care 7, 249\u2013254 (2004).","journal-title":"Current opinion in clinical nutrition and metabolic care"},{"key":"BFsrep10701_CR30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1042\/BJ20130262","volume":"456","author":"A Hofmeister-Brix","year":"2013","unstructured":"Hofmeister-Brix, A., Lenzen, S. & Baltrusch, S. The ubiquitin-proteasome system regulates the stability and activity of the glucose sensor glucokinase in pancreatic beta-cells. The Biochemical journal 456, 173\u2013184 (2013).","journal-title":"The Biochemical journal"},{"key":"BFsrep10701_CR31","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1745-7254.2008.00744.x","volume":"29","author":"J Wang","year":"2008","unstructured":"Wang, J. et al. Effects of ABCA1 variants on rosiglitazone monotherapy in newly diagnosed type 2 diabetes patients. Acta pharmacologica Sinica 29, 252\u2013258 (2008).","journal-title":"Acta pharmacologica Sinica"},{"key":"BFsrep10701_CR32","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/j.1745-7254.2008.00840.x","volume":"29","author":"YY He","year":"2008","unstructured":"He, Y. Y. et al. Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients. Acta pharmacologica Sinica 29, 983\u2013989 (2008).","journal-title":"Acta pharmacologica Sinica"},{"key":"BFsrep10701_CR33","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews, D. R. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412\u2013419 (1985).","journal-title":"Diabetologia"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep10701","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep10701.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep10701.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T23:32:19Z","timestamp":1672961539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep10701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,29]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,9,1]]}},"alternative-id":["BFsrep10701"],"URL":"https:\/\/doi.org\/10.1038\/srep10701","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,29]]},"assertion":[{"value":"8 January 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10701"}}